July 23, 2013
/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its second quarter 2013 financial results on
Tuesday, August 6, 2013
, after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at
4:30 p.m. EDT
9:30 p.m. IST
to provide a business and financial update and discuss second quarter 2013 financial results.
Interested parties may access the live audio webcast via the Investors & Media section of the Jazz Pharmaceuticals website at
. Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast. A replay of the webcast will be archived on the website for one week.
Audio webcast/conference call:
U.S. Dial-In Number: +1 877 280 4953International Dial-In Number: +1 857 244 7310Passcode: 10594339
A replay of the conference call will be available through
August 13, 2013
and accessible through one of the following telephone numbers and entering the passcode:Replay U.S. Dial-In Number: +1 888 286 8010 Replay International Dial-In Number: +1 617 801 6888Passcode: 72340817
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide) intrathecal infusion and FazaClo® (clozapine, USP) HD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its EUSA Pharma division. For further information, see